Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.82 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.50 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87612 | 0.91 | GBA1 (1.00) | GBA1PRMT6CARM1PRMT3PRMT1 | |
| Bromide SCHEMBL10728442 | 0.89 | GBA1 (0.96) | GBA1PRMT6CARM1PRMT3PRMT1 | |
| Hydrochloric Acid SCHEMBL4935892 | 0.89 | GBA1 (0.96) | GBA1PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL8101593 | 0.86 | GBA1 (0.82) | GBA1PRMT6CARM1PRMT3PRMT1 | |
| Formaldehyde SCHEMBL28466516 | 0.85 | GBA1 (0.89) | GBA1PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL1428015 | 0.84 | GBA1 (0.85) | GBA1CCR3SLC6A4 | |
| SCHEMBL8891663 | 0.84 | GBA1 (0.85) | GBA1CCR3SLC6A4POLB | |
| SCHEMBL28128332 | 0.82 | GBA1 (0.82) | GBA1CCR3SLC6A4 | |
| SCHEMBL9400535 | 0.81 | GBA1 (0.79) | GBA1CCR3 | |
| Hydrochloric Acid SCHEMBL28021554 | 0.81 | GBA1 (0.79) | GBA1CCR3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| EP-2155748-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008144268-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008117148-A1 | SUBSTITUTED OXADIAZOLE ANALOGS AS CALCIUM CHANNEL ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, AGTR1, AGTR2 | GBA1 1453/4885PRMT6 2129/4885CARM1 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.